Watch An Introduction to the PRESIDIO Clinical Trial of KZR-616 for the Treatment of Polymyositis and Dermatomyositis

Learn more about PRESIDIO

Dr. Mary Katherine (MK) Farmer, MD, Rheumatologist and Senior Medical Director at Kezar Life Sciences, joined us live on Rare Disease Day 2020 and introduced Kezar, KZR-616, and the PRESIDIO Clinical Study.

In this video, Dr. Farmer discusses the science behind KZR-616, an investigational treatment for autoimmune diseases, and provides an overview of PRESIDIO, a phase 2 study of KZR-616 in Polymyositis and Dermatomyositis which is currently enrolling in trial sites across the U.S.

Kezar Presentation Slides

View/Download the presentation slides.

Share these with your physician if you are eligible and interested in participating in this phase 2 clinical trial.

Learn more about PRESIDIO

Visit the Kezar Life Sciences PRESIDIO website to learn more about the clinical trial.

And, email Kezar with questions or interest at clinicaltrials@Kezarbio.com

Learn more about Polymyositis, Dermatomyositis, and Necrotizing Myopathy

Learn more about the types of myositis for which Kezar is current recruiting, including polymyositis, dermatomyositis, and immune-mediated necrotizing myopathy.

About Dr. MK Farmer, MD

Dr. MK Farmer, Kezar Life SciencesDr. Mary Katherine (MK) Farmer, MD received her medical training at the Medical College of Georgia, graduating in 2001. She completed her Internal Medicine training at the University of South Carolina (USC) from 2001-2004 where she first became interested in rheumatology. From 2004-2006 she worked as an inpatient hospitalist in Charleston, SC, and then on faculty at USC. She attended the University of North Carolina at Chapel Hill (UNC) from 2006-2009 for Rheumatology Fellowship and was invited to present her research on lupus nephritis and mycophenolate mofetil (CellCept®) at national and local conferences.

She was diagnosed with dermatomyositis in 2003 during residency and left clinical practice in 2010 to pursue a career in clinical research with her strong foundation in autoimmune diseases. She has worked with most of the major pharmaceutical companies and has worked on several medications that have been approved for different diseases.

She came to Kezar Life Sciences in mid-2019 to take a once-in-a-lifetime opportunity to run the myositis development program.

About Kezar Life Sciences

A sponsor of Myositis Support and Understanding (MSU)

Kezar Life Sciences, a 2020 sponsor of MSU and Myositis LIFEFounded in 2015 and based in South San Francisco, Kezar Life Sciences is a clinical-stage biotechnology company committed to revolutionizing treatments for patients with autoimmune diseases and cancer. Kezar is translating its innovative research on the immunoproteasome and protein secretion pathways to advance novel therapeutic approaches. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in severe and underserved autoimmune diseases. Kezar believes that the immunoproteasome is a validated target for the treatment of a wide variety of autoimmune diseases given the compelling published activity seen with non-selective proteasome inhibitors administered to patients with severe autoimmune diseases.

Kezar is currently recruiting patients to participate in Phase 2 clinical trials. The diseases being studied in these trials are: lupus nephritis, dermatomyositis, polymyositis, autoimmune hemolytic anemia, and immune thrombocytopenia.

See more educational myositis videos

Tags:

Author:

Myositis Support and Understanding Association (MSU) is a patient-centered, all-volunteer 501(c)(3) nonprofit organization Empowering the Myositis Community. Founded by Myositis patients, for Myositis patients, MSU provides education, support, advocacy, access to research and clinical trial matching, and need-based financial assistance.

View more information: Myositis Support

0 Comments

Leave a reply

Your email address will not be published. Required fields are marked *

*

This site uses Akismet to reduce spam. Learn how your comment data is processed.

© 2020 Myositis Support and Understanding Association (MSU). All rights reserved. | View our Privacy Policy, Terms, and Non-Discrimination policy. MSU is a charitable organization with 501(c)(3) tax-exempt status. Federal ID #47-4570748.

The best way to prevent catching or spreading coronavirus is thorough hand washing, social distancing, and social isolation. Should you begin experiencing symptoms of coronavirus, which include fever, cough, and shortness of breath, please contact your doctor immediately. View COVID-19 resources and updates, and stay tuned to your state, local, and federal health agencies, along with the CDC.

Log in with your credentials

or    

Forgot your details?

Register

Send this to a friend